Biocon Biologics Limited (BBL), a subsidiary of Biocon, and Serum Institute Life Sciences Private Limited (SILS), a subsidiary of Serum Institute of India Pvt. Ltd., has announced a strategic alliance. As
Health Canada has granted full approval to Moderna’s Spikevax and Pfizer-BioNTech’s Comirnaty Covid-19 vaccines for use in individuals aged 12 years and above. The regulator originally authorised Moderna’s
Hookipa Pharma has signed a clinical collaboration and supply agreement with Merck to assess HB-200 in combination with Keytruda (pembrolizumab) in patients with advanced head and neck squamous
Eli Lilly and Company has announced that the US government is set to purchase additional doses of its neutralising antibody therapy, etesevimab, to treat Covid-19. Under the terms
The US Department of Health and Human Services (HHS) and the Department of Defense (DOD) have signed an agreement with Regeneron Pharmaceuticals to buy additional doses of the
Sanofi has completed the acquisition of messenger RNA (mRNA) therapies firm Translate Bio to expedite the use mRNA technology for the development of treatments and vaccines. The latest move
US-based biopharmaceutical firm AzurRx BioPharma has agreed to acquire clinical-stage biotechnology company First Wave Bio in a stock-and-cash deal valued at $229m. First Wave Bio is focussing on
The UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) has approved Amgen’s sotorasib (Lumakras) to treat patients with specific non-small cell lung cancer with KRAS G12C mutation. To be
A first-in class antibody, lenzilumab binds to and neutralises granulocyte-macrophage colony-stimulating factor (GM-CSF). GM-CSF is a key cytokine that causes a hyperinflammatory cascade or cytokine storm associated to
The Phase 2, two-arm, randomised, double blind, placebo controlled, multicentre study will evaluate the efficacy and safety of Ampligen in 80 subjects suffering with PCCD. This trial will
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.